Targeting the undruggable oncogenic KRAS: the dawn of hope

  title={Targeting the undruggable oncogenic KRAS: the dawn of hope},
  author={Hande Asimgil and Utku Ertetik and Nedim Can Çevik and Menar Ekizce and Alper Doğru{\"o}z and Muazzez G{\"o}kalp and Elif Arık-Sever and Rouzanna Istv{\'a}nffy and Helmut Friess and G{\"u}ralp O Ceyhan and Ihsan Ekin Demir},
  journal={JCI Insight},
KRAS mutations are the drivers of various cancers, including non–small cell lung cancer, colon cancer, and pancreatic cancer. Over the last 30 years, immense efforts have been made to inhibit KRAS mutants and oncogenic KRAS signaling using inhibitors. Recently, specific targeting of KRAS mutants with small molecules revived the hopes for successful therapies for lung, pancreatic, and colorectal cancer patients. Moreover, advances in gene editing, protein engineering, and drug delivery… 

Figures and Tables from this paper

Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling

The underlying mechanism of hepatocytic Kras/Erk-driven mTOR activation and its downstream targets (PEG3 and STAT3) in HCC is revealed, and PEG3 is identified as a new prognostic biomarker for HCC with Kras /Erk and mTOR hyperactivation, and a potential therapeutic strategy for this subset of HCC patients is provided.

KRAS mutations as essential promoters of lymphangiogenesis via extracellular vesicles in pancreatic cancer

In this issue of the JCI, Luo, Li, et al. explored the relationship between the presence of the KRASG12D mutation and lymphangiogenesis in PDAC and used in vitro and in vivo models and an elegant mechanistic approach to describe an alternative pathway for lymphang iogenesis promotion.

Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner

The assessment of the KRAS status in advanced-stage NS-NSCLC has become essential to setting up an optimal therapeutic strategy in these patients, leading to new challenges for thoracic oncologists.

Systematic Analysis of KRAS-ligand Interaction Modes and Flexibilities Reveals the Binding Characteristics

The features ofKRAS binding pockets and ligand-binding characteristics of KRAS complexes using a structural systems pharmacology approach are provided to facilitate rational KRAS drug design.

The Trinity: Interplay among Cancer Cells, Fibroblasts, and Immune Cells in Pancreatic Cancer and Implication of CD8+ T Cell-Orientated Therapy

A functional network for how cancer cells, fibroblasts, and immune cells communicate with each other in the tumor microenvironment is proposed and the future application of CD8+ T cell-oriented therapy in the treatment of pancreatic cancer is pointed out.

Expression, Prognostic Value, and Functional Mechanism of the KDM5 Family in Pancreatic Cancer

KDM5 family members may be prognostic markers and new therapeutic targets for patients with pancreatic cancer and the results of gene ontology and pathway analyses showed that many gene terms related to cell proliferation, migration and many carcinogenic pathways were shown.

Direct GDP-KRASG12C inhibitors and mechanisms of resistance: the tip of the iceberg

  • Joshua C. RosenAdrian SacherMing-Sound Tsao
  • Biology
    Therapeutic Advances in Medical Oncology
  • 2023
The preclinical development of KRASG12C inhibitors, their clinical evaluations, different types of resistance mechanisms to these compounds, and ways of overcoming them are summarized.



New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness

An update on the most recent advances in KRAS-mutant lung cancer is provided, with a focus on mechanistic insights into tumor heterogeneity, the potential clinic implications and new therapies on horizons tailored for KRas-mutants lung cancer.

Cancer vaccines: Targeting KRAS-driven cancers

This review summarizes the development and progress of vaccines targeting KRAS and evaluates their potential benefits and obstacles in the current landscape of therapy for KRAS-driven cancers.

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

The safety of this approach was demonstrated in mice and monkeys with KRAS ASOs that produced robust target knockdown in a broad set of tissues without any adverse effects, and data suggest that AZD4785 is an attractive therapeutic for the treatment of KRAS-driven human cancers and warrants further development.

RAS-targeted therapies: is the undruggable drugged?

How drugs that target RAS or associated pathways might be used effectively, particularly in combinations, are explored, and other RAS-targeted therapies in the pipeline are discussed, including combination strategies.

Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles

It is demonstrated that a peptide based, oligonucleotide condensing, endosomolytic nanoparticle (NP) system is avidly taken up by cancer cells in vitro, can deliver KRAS-specific siRNA, inhibit KRAS expression, and reduce cell viability, and can deliver siRNA to the tumor microenvironment.

KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment.

The most emergent perspectives on the relationship between KRAS-mutant cancer cells and their microenvironment components are discussed, including its effects on the components of the tumor microenvironment.

Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs

A proof-of-concept approach to therapeutic KRAS targeting using nanoparticle delivery of siRNA is demonstrated, which highlights the potential translational impact of therapeutic RNA interference, which may have broad applications in oncology, especially for traditional “undruggable” targets.

Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer

The results demonstrate an approach for direct and specific targeting of oncogenic KRAS in tumours using iExosomes, and suppressed cancer in multiple mouse models of pancreatic cancer and significantly increased overall survival.

Immune modulatory effects of oncogenic KRAS in cancer

The preclinical work on KRAS-induced inflammation and immune modulation in the context of currently ongoing clinical trials targeting cancer entities that carry KRAS mutations and strategies to overcome the oncogene-induced effects on the immune system are discussed.

Therapeutics Targeting Mutant KRAS.

A revolutionary strategy to use covalent allosteric inhibitors that target a shallow pocket on the KRAS surface has provided new impetus for renewed drug development efforts, specifically against KRASG12C.